Research map: Unexpected Lack of Efficacy of Liposomal-Encapsulated Daunorubicin/Cytarabine in Pediatric FLT3 Wild-Type Newly Diagnosed AML

Back to the article

Papers in this map

  1. Improved Outcome in Pediatric Relapsed Acute Myeloid Leukemia: Results of a Randomized Trial on Liposomal Daunorubicin by the International BFM Study Group · Gertjan J.L. Kaspers · 2013 · 237 citations · Cited by this paper
  2. Statistical and Methodological Considerations in the Evaluation of Ultra-Low-Dose Nivolumab · 2026 · Related
  3. Occurrence of Treatment-Related Cardiotoxicity and Its Impact on Outcomes Among Children Treated in the AAML0531 Clinical Trial: A Report From the Children’s Oncology Group · Kelly Getz · 2018 · 107 citations · Cited by this paper
  4. Virtual Sustained Tobacco Treatment for Patients With Cancer: A Randomized Controlled Trial (ECOG-ACRIN: EAQ171CD) Within the National Cancer Institute Community Oncology Research Program · 2026 · Related
  5. Phase I/II Study of CPX-351 Followed by Fludarabine, Cytarabine, and Granulocyte-Colony Stimulating Factor for Children With Relapsed Acute Myeloid Leukemia: A Report From the Children’s Oncology Group · Todd M. Cooper · 2020 · 68 citations · Cited by this paper
  6. Innovate or Be Left Behind: A Path to Prospective External Control Arms for Accelerated Oncology Drug Development · 2026 · Related
  7. Acute myeloid leukemias with UBTF tandem duplications are sensitive to menin inhibitors · Juan Martin Barajas · 2023 · 64 citations · Cited by this paper
  8. AAML1831: A Phase III Trial Comparing Standard Induction Therapy With CPX-351 in De Novo Pediatric AML: A Report From the Children's Oncology Group · 2026 · Related
  9. Effect of Dexrazoxane on Left Ventricular Systolic Function and Treatment Outcomes in Patients With Acute Myeloid Leukemia: A Report From the Children’s Oncology Group · Kelly Getz · 2020 · 63 citations · Cited by this paper
  10. Clinical and Psychological Outcomes After Monoclonal Gammopathy Screening: A Population-Based Screening Study and Subsequent Randomized Trial of Follow-Up · 2026 · Related
  11. Mitoxantrone Versus Liposomal Daunorubicin in Induction of Pediatric AML With Risk Stratification Based on Flow Cytometry Measurement of Residual Disease · Anne Maria Tierens · 2024 · 46 citations · Cited by this paper
  12. Phase I/II Study of Sonrotoclax (BGB-11417) Monotherapy in Patients With Mantle Cell Lymphoma Previously Treated With Anti-CD20 Therapy and a Bruton Tyrosine Kinase Inhibitor · 2026 · Related
  13. Diagnosis and management of AML in pediatric patients: consensus recommendations from an international expert panel · Christian Michel Zwaan · 2025 · 25 citations · Cited by this paper
  14. SKYSCRAPER-01: Tiragolumab in Combination With Atezolizumab in Previously Untreated PD-L1–High, Locally Advanced, Unresectable or Metastatic Non–Small Cell Lung Cancer · 2026 · Related
  15. NUP98 oncofusions in myeloid malignancies: An update on molecular mechanisms and therapeutic opportunities · Milad Rasouli · 2024 · 22 citations · Cited by this paper
  16. Moderate Hypofractionation for Regional Node Irradiation Is Safe and Effective · 2026 · Related
  17. Population Pharmacokinetics and Exposure‐Response Analyses for CPX‐351 in Patients With Hematologic Malignancies · Qi Wang · 2018 · 10 citations · Cited by this paper
  18. Beyond Statistical Significance: Methodological Fragility and Censoring Bias in the 5-Year Update of CheckMate 743 · 2026 · Related
  19. Cardiotoxicity of CPX-351 in children and adolescents with relapsed AML: a Children's Oncology Group report · Kasey Joanne Leger · 2024 · 7 citations · Cited by this paper
  20. Limiting Dexamethasone Exposure With Highly Emetogenic Chemotherapy Regimens: Is the Verdict In? · 2026 · Related
  21. CPX-351 in Down syndrome–associated myeloid leukemia: results and prognostic factors from the phase 3 ML-DS 2018 trial · Stephanie Laszig · 2025 · 7 citations · Cited by this paper
  22. Synergistic Cytarabine:Daunorubicin Ratios Delivered by CPX-351 to Human Leukemia Xenografts Is Associated with Liposome-Mediated Bone Marrow Drug Accumulation, Intracellular Delivery of Encapsulated Agents to Leukemia Cells, and Increased Efficacy. · Lawrence D. Mayer · 2008 · 3 citations · Cited by this paper

Source: OpenAlex (CC0)